Saturday 17 October 2026
Export PRVA’s income statement to Excel — free account
Privia Health Group, Inc.
PRVA Healthcare Health Information Services
Privia Health Group, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.1 billion, up 22.3% from fiscal 2024. In the quarter to June 2026, revenue grew 21.4%, EPS grew 250.0% and free cash flow fell 86.2%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three.
22.46
0.16
−0.71%
Follow PRVA
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
116.95 | 121.00 | 131.72 | 166.00 |
+8 more quarters Free account |
P/S ratio |
1.38 | 1.14 | 1.36 | 1.50 | |
P/FCF ratio |
24.80 | 18.55 | 17.76 | 27.69 | |
P/Operating CF |
2,950.08 | (51.63) | 22.72 | 58.79 | |
P/B ratio |
3.87 | 3.17 | 3.66 | 4.01 | |
Price to Tangible BV |
8.04 | 6.66 | 7.93 | 7.23 | |
EV/Sales |
1.21 | 0.96 | 1.15 | 1.30 | |
EV/EBITDA |
50.31 | 45.38 | 55.47 | 70.99 | |
EV/Operating CF |
21.84 | 15.69 | 14.99 | 23.91 | |
EV/FCF |
21.89 | 15.73 | 15.01 | 23.97 | |
Quick Ratio |
1.55 | 1.55 | 1.55 | 1.61 | |
Current Ratio |
1.62 | 1.61 | 1.60 | 1.67 | |
Net Debt/EBITDA |
(27.25) | (39.20) | (34.42) | (25.71) | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
1.71 | 1.73 | 1.69 | 1.64 | |
Operating CF/Net income |
0.12 | (16.14) | 13.93 | 7.58 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
7.53% | 8.22% | 6.60% | 8.03% | |
Intangible Assets out of Total Assets |
0.29 | 0.30 | 0.31 | 0.25 | |
Share Based Compensation of Revenue |
3.07% | 3.63% | 2.86% | 3.27% | |
Graham Net Nets |
0.12 | 0.14 | 0.11 | 0.13 | |
Graham Number |
5.74 | 4.98 | 5.12 | 4.58 | |
Earnings Yield |
0.86% | 0.83% | 0.76% | 0.60% | |
Free Cash Flow Yield |
4.03% | 5.39% | 5.63% | 3.61% | |
Revenue per Share |
5.02 | 4.86 | 4.43 | 4.73 | |
Operating CF per Share |
0.01 | (0.40) | 1.04 | 0.42 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.01 | (0.40) | 1.04 | 0.42 | |
Cash per Share |
3.27 | 3.38 | 3.93 | 3.60 | |
Shareholders Equity per Share |
6.65 | 6.49 | 6.47 | 6.21 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
6.65 | 6.49 | 6.47 | 6.21 | |
Free Cash Flow |
1.10 | (49.46) | 127.50 | 51.99 | |
Working Capital |
390.82 | 364.72 | 342.48 | 388.01 | |
Net Current Asset Value |
374.76 | 354.03 | 332.57 | 382.70 | |
EV/EBIT |
63.83 | 59.44 | 71.52 | 93.85 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
72.31 | 70.09 | 84.62 | 108.38 | |
| Other line items | |||||
Average Receivables |
509.08 | 451.20 | 358.54 | 454.00 | |
Average Payables |
82.65 | 74.35 | 89.40 | 75.15 | |
Average Assets |
1,380.56 | 1,300.72 | 1,252.58 | 1,248.28 | |
Average Common Equity |
785.81 | 757.72 | 737.20 | 712.47 |
Columns are period end dates